Bardoxolone methyl (BARD), an activator of Nrf2, was first tested in a phase I cancer trial, in which Nrf2 activation was found to significantly improve estimated glomerular filtration rate (eGFR) [94]. This evidence concerns the gene NFE2L2 and cancer.